Page 14 - Urovant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant ... Sumitovant BiopharmaFebruary 18, 2021 GMT New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine published Myovant Sciences’ Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and...

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results SEC reviewing preliminary proxy statement for the previously announced merger of the Company with Sumitovant Biopharma Special General Meeting of Shareholders to approve the merger is expected to occur by the end of 1Q CY2021 U.S. commercial launch of GEMTESA (vibegron) to treat OAB is on track for late-Q1 CY2021, following U.S. FDA approval in December 2020 Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended December 31, 2020. "The third quarter of fiscal 2020 ...

(1) Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI). URO-902 has the potential to be the first gene therapy for patients with OAB. Following the recommendation of the DSMB, Urovant is proceeding with opening cohort 2 of the study with a dose of 48 mg or placebo. About the Phase 2a Study This randomized, double blind, placebo-controlled study will evaluate the ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to ... Sumitovant BiopharmaDecember 28, 2020 GMT Myrtle Potter, CEO Sumitovant Biopharma “By forming a transformative collaboration with Myovant Sciences and Pfizer, we have taken steps to help position ORGOVYX for advanced prostate cancer and relugolix once-daily combination for Women’s Health for success.” Myrtle Potter, CEO Sumitovant Biopharma “By forming a transformative collaboration with Myovant Sc...

Urovant Sciences Ltd. (NASDAQ: UROV) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of  Urovant Sciences Ltd. (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the company by Sumitovant Biopharma Ltd., UROV's majority shareholder that currently owns 72% of the company's outstanding common shares.  Under the terms of the acquisition agreement, the company's shareholders will receive only $16.25 in cash for each share of UROV common stock that they own .  If you own UROV shares and wish to ...